| Schedule Of equity and cash consideration payment |
Date | | Cash | | | Shares of Common Stock | | July 1, 2020 | | $ | 300,000 | | | | 222,223 | | December 31, 2020 (paid January 4, 2021) | | | 75,000 | | | | - | | November 1, 2020 | | | - | | | | 101,392 | | February 1, 2021 | | | - | | | | 101,392 | | March 31, 2021 (paid April 2, 2021) | | $ | 75,000 | | | | - | | June 1, 2021 (issued June 25, 2021) | | | - | | | | 101,392 | | September 1,2021 | | | - | | | | 306,935 | | Total Consideration | | $ | 450,000 | | | | 833,334 | |
|
| Schedule of acquisition payable |
Date | | Consideration | | Acquisition | | $ | 3,350,000 | | July 1, 2020 – cash | | | (200,000 | ) | July 1, 2020 - equity consideration (222,222 common shares of the acquirer) * | | | (340,000 | ) | November 1, 2020 - equity consideration (101,389 common shares of the acquirer) * | | | (155,125 | ) | January 4, 2021 – cash | | | (75,000 | ) | February 1, 2021 - equity consideration (101,932 common shares of the acquirer) * | | | (155,130 | ) | March 31, 2021 | | | (75,000 | ) | June 1, 2021 - equity consideration (101,400 common shares of the acquirer) | | | (584,869 | ) | Acquisition payable ** | | $ | 1,764,876 | |
|
| Schedule of pro forma |
Pro Forma, Unaudited | | | | | | | | | | | | | | Proforma | | | | | Year ended June 30, 2022 | | Upexi, Inc. | | | VitaMedica | | | Interactive | | | Cygnet | | | Adjustments | | | Proforma | | | | | | | | | | | | | | | | | | | | | Net sales | | $ | 44,584,996 | | | $ | 384,391 | | | $ | 416,700 | | | $ | 22,583,781 | | | $ | | | $ | 67,969,868 | | Cost of sales | | $ | 19,396,123 | | | $ | 93,509 | | | $ | - | | | $ | 19,117,296 | | | $ | | | $ | 38,606,928 | | Operating expenses | | $ | 27,841,203 | | | $ | 255,286 | | | $ | 795,507 | | | $ | 2,086,722 | | | $ | 1,767,350 | | | $ | 32,746,068 | | Net income (loss) | | $ | (2,046,030 | ) | | $ | 35,596 | | | $ | (378,807 | ) | | $ | 1,117,971 | | | $ | (1,767,350 | ) | | $ | (3,038,620 | ) | Basic income (loss) per common share | | $ | (0.13 | ) | | $ | 0.36 | | | $ | (0.68 | ) | | $ | 2.01 | | | $ | | | $ | (0.17 | ) | Weighted average shares outstanding | | | 16,224,520 | | | | 100,000 | | | | 560,170 | | | | 555,489 | | | | | | | | 17,440,179 | |
Pro Forma, Unaudited | | | | | | | | | | | | | | Proforma | | | | | Year ended June 30, 2021 | | Upexi, Inc. | | | VitaMedica | | | Interactive | | | Cygnet | | | Adjustments | | | Proforma | | | | | | | | | | | | | | | | | | | | | Net sales | | $ | 24,095,025 | | | $ | 4,109,443 | | | $ | 1,790,714 | | | $ | 30,111,708 | | | $ | | | $ | 29,995,182 | | Cost of sales | | $ | 12,196,123 | | | $ | 1,117,547 | | | $ | - | | | $ | 25,489,728 | | | $ | | | $ | 13,313,670 | | Operating expenses | | $ | 10,472,165 | | | $ | 2,743,824 | | | $ | 2,683,937 | | | $ | 2,782,296 | | | $ | 3,200,304 | | | $ | 19,100,230 | | Net income (loss) | | $ | 2,978,948 | | | $ | 380,047 | | | $ | (783,342 | ) | | $ | 1,485,628 | | | $ | (3,200,304 | ) | | $ | (624,651 | ) | Basic income (loss) per common share | | $ | 0.25 | | | $ | 3.80 | | | $ | (1.40 | ) | | $ | 2.67 | | | $ | | | $ | (0.05 | ) | Weighted average shares outstanding | | | 11,930,378 | | | | 100,000 | | | | 560,170 | | | | 555,489 | | | | | | | | 12,590,548 | |
|